title: Evaluation of an MRI-based score of disease activity in perianal fistulizing Crohn's disease.
abstract: To evaluate a magnetic resonance imaging (MRI)-based score of disease severity for perianal fistulizing Crohn's disease (CD), 16 patients with perianal fistulizing CD underwent 1.5-T MRI before and after infliximab therapy. MRI scores, Perianal Disease Activity Index (PDAI) and C-reactive protein (CRP) were calculated, and fistula drainage was assessed. These items were compared for responders and nonresponders. After therapy, PDAI values and CRP values decreased significantly in responders, but there were no significant differences in the MRI scores. In all responders, MRI findings were indicative of persisting active inflammation. In these patients, a relapse rate of 57% was seen.
authors.affiliation: Department of Radiology, Academic Medical Center, University of Amsterdam, 1105 AZ, The Netherlands.
authors.forename: Karin
authors.initials: K
authors.lastname: Horsthuis
authors.forename: Manon L W
authors.initials: ML
authors.lastname: Ziech
authors.forename: Shandra
authors.initials: S
authors.lastname: Bipat
authors.forename: Anje M
authors.initials: AM
authors.lastname: Spijkerboer
authors.forename: Annette C
authors.initials: AC
authors.lastname: de Bruine-Dobben
authors.forename: Daniel W
authors.initials: DW
authors.lastname: Hommes
authors.forename: Jaap
authors.initials: J
authors.lastname: Stoker
mesh_terms: D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D015415:Biomarkers / Q000032:analysis; D002097:C-Reactive Protein / Q000032:analysis; D003424:Crohn Disease / Q000188:drug therapy / Q000473:pathology*; D005260:Female; D019786:Gadolinium DTPA; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D000069285:Infliximab; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008875:Middle Aged; D012003:Rectal Fistula / Q000473:pathology*; D012720:Severity of Illness Index; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D015415:Biomarkers; D005765:Gastrointestinal Agents; C064925:gadodiamide; D002097:C-Reactive Protein; D000069285:Infliximab; D019786:Gadolinium DTPA